Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct 22:15:8151-8166.
doi: 10.2147/IJN.S272529. eCollection 2020.

Recent Clinical Developments of Nanomediated Drug Delivery Systems of Taxanes for the Treatment of Cancer

Ruben A G van Eerden  1 , Ron H J Mathijssen  1 , Stijn L W Koolen  1   2
Affiliations
Review

Recent Clinical Developments of Nanomediated Drug Delivery Systems of Taxanes for the Treatment of Cancer

Ruben A G van Eerden et al. Int J Nanomedicine. .

Abstract

Conventional taxanes are used as cornerstone of the chemotherapeutical treatment for a variety of malignancies. Nevertheless, a large proportion of patients do not benefit from their treatment while they do suffer from severe adverse events related to the solvent or to the active compound. Cremophor EL and polysorbate 80 free formulations, conjugates, oral formulations and different types of drug delivery systems are some examples of the several attempts to improve the treatment with taxanes. In this review article, we discuss recent clinical developments of nanomediated drug delivery systems of taxanes for the treatment of cancer. Targeting mechanisms of drug delivery systems and characteristics of the most commonly used taxane-containing drug delivery systems in the clinical setting will be discussed in this review.

Keywords: cancer; drug delivery systems; nanomedicine; nanoparticle; taxane.

PubMed Disclaimer

Conflict of interest statement

This review was performed without external funding. Ron HJ Mathijssen and Stijn LW Koolen received an unrestricted grant of Cristal Therapeutics (producer of CPC634) for a phase I clinical trial with this nanomedicine agent. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Schematic impression of active targeting drug delivery systems. Surface markers varies between healthy and tumor tissue. An targeting drug delivery system has one specific target which causes a release of the payload if the drug delivery system is bound to the target. When the target is not expressed or not bound the drug delivery system will not release its payload and will be transported to others locations. This figure was created with BioRender.com.
Figure 2
Figure 2
Schematic impression of EPR effect and nanoparticles. The fenestrae in the vascular wall of the tumor are wider than in normal tissue and the smooth muscle cells in the vascular wall are arranged in a chaotic manner compared to healthy tissue. Nanoparticles and conventional taxanes can easily pass the vascular wall inside the tumor. In contrast, the endothelial cells and smooth muscle cells are good aligned in the vascular wall of healthy tissue, which makes it hard for nanoparticle to cross the wall while conventional taxanes can still penetrate inside healthy tissue. This figure was created with BioRender.com.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bristol-Myers Squibb Company. Taxol (Paclitaxel). U.S. Food and Durg Administration website. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020262s049lbl.pdf. Accessed June30, 2020.
    1. Sanofi-aventis U.S. LLC. Taxotere (Docetaxel). U.S. Food and Drug Administration website. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020449s071lbl.pdf. Accessed June30, 2020.
    1. Sanofi-aventis U.S. LLC. Jevtana (Cabazitaxel). U.S. Food and Drug Administration website. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201023lbl.pdf. Accessed June30, 2020.
    1. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc. 1971;93(9):2325–2327. doi:10.1021/ja00738a045 - DOI - PubMed
    1. Ringel I, Horwitz SB. Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst. 1991;83(4):288–291. doi:10.1093/jnci/83.4.288 - DOI - PubMed

MeSH terms

LinkOut - more resources